NKGen Biotech, Inc. - NKGN

SEC Filings Our NKGN Tweets

About Gravity Analytica

Recent News

07.02.2026 - NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
05.19.2026 - NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment
04.09.2026 - NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
03.23.2026 - NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
03.10.2026 - NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026

Recent Filings